X4 Pharmaceuticals restructures; Cytokinetics targets $650M raisenews2025-09-17T14:42:49+00:00September 17th, 2025|Endpoints News|
Ark, Atom file to go public in Hong Kong; Aptevo’s stock rallies on AML datanews2025-09-16T14:58:22+00:00September 16th, 2025|Endpoints News|
FDA expands label for Krystal’s gene therapy; The latest on Novo Nordisk’s Wegovynews2025-09-15T14:40:33+00:00September 15th, 2025|Endpoints News|
A new biotech fund in the Middle East; Xspray preps for FDA decision on Dasynocnews2025-09-12T14:46:45+00:00September 12th, 2025|Endpoints News|
Maze’s SLC6A19 inhibitor moves to Phase 2; GenFleet to go public in Hong Kongnews2025-09-11T14:43:29+00:00September 11th, 2025|Endpoints News|
PMV to pursue FDA approval in ovarian cancer; Amylyx reveals $175M offeringnews2025-09-10T14:04:01+00:00September 10th, 2025|Endpoints News|
Regeneron’s promising antibody for cat, birch allergies; Ascletis targets quarterly GLP-1 shotnews2025-09-09T14:51:27+00:00September 9th, 2025|Endpoints News|
BridgeBio’s Phase 2 hypoparathyroidism data; FDA clears second pig kidney trialnews2025-09-08T14:11:52+00:00September 8th, 2025|Endpoints News|
Rapafusyn Pharmaceuticals’ $44M raise; CAGE Bio’s atopic dermatitis datanews2025-09-05T14:19:49+00:00September 5th, 2025|Endpoints News|
Avadel’s $20M upfront for sleep drug; Congruence gets $32M for obesity drugnews2025-09-04T13:57:12+00:00September 4th, 2025|Endpoints News|
